| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT05117008) | Medical College of Wisconsin | 2022-07-19 |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (NCT05431608) | Memorial Sloan Kettering Cancer Center | 2022-06-20 |
| A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (NCT05430945) | Zhejiang University | 2022-06-20 |
| Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab (NCT05053607) | Pack Health | 2022-06-17 |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (NCT05170789) | Tulane University School of Medicine | 2022-04-27 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) (NCT06400264) | National Cancer Institute (NCI) | 2022-02-22 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (NCT04843579) | Weill Medical College of Cornell University | 2021-12-29 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab (NCT04302324) | Weill Medical College of Cornell University | 2021-10-28 |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma (NCT05577000) | Thomas Martin, MD | 2021-10-18 |
| TriPRIL CAR T Cells in Multiple Myeloma (NCT05020444) | Marcela V. Maus, M.D.,Ph.D. | 2021-10-05 |
| Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT04883242) | University of Washington | 2021-07-29 |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma (NCT05150522) | Shenzhen University General Hospital | 2021-07-01 |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (NCT04355039) | Medical College of Wisconsin | 2021-07-01 |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial (NCT04764942) | Mayo Clinic | 2021-05-06 |
| Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (NCT04790474) | Tel-Aviv Sourasky Medical Center | 2021-03-25 |
| A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma (NCT04398485) | Ionis Pharmaceuticals, Inc. | 2021-01-20 |
| A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (NCT04670055) | Zhejiang University | 2021-01-01 |
| Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. (NCT04519476) | Oncotherapeutics | 2020-11-01 |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma (NCT04434469) | Genentech, Inc. | 2020-07-08 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM (NCT04176718) | Andrew Yee, MD | 2020-05-18 |
| Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma (NCT04119336) | Andrew Yee, MD | 2020-02-14 |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment (NCT03770260) | National Cancer Institute (NCI) | 2020-02-10 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) (NCT04083534) | Regeneron Pharmaceuticals | 2019-09-26 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (NCT06400251) | National Cancer Institute (NCI) | 2019-08-08 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) (NCT06400225) | National Cancer Institute (NCI) | 2019-07-24 |
| CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT03798678) | National Cancer Institute (NCI) | 2019-07-08 |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma (NCT04162353) | iCell Gene Therapeutics | 2019-07-01 |
| Carfilzomib in Combination for the Treatment of RR MM (NCT04004338) | Black Sea Hematology Association | 2019-04-14 |
| TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03952091) | TJ Biopharma Co., Ltd. | 2019-03-27 |
| TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03860038) | TJ Biopharma Co., Ltd. | 2019-01-28 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (NCT06400238) | National Cancer Institute (NCI) | 2018-10-15 |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (NCT03520985) | Swiss Cancer Institute | 2018-10-01 |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma (NCT03731832) | GWT-TUD GmbH | 2018-09-20 |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (NCT03601624) | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 2018-09-01 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) (NCT06308822) | National Cancer Institute (NCI) | 2018-08-20 |
| SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma (NCT03589222) | PETHEMA Foundation | 2018-07-15 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) (NCT05490771) | National Cancer Institute (NCI) | 2018-06-20 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (NCT03031730) | National Cancer Institute (NCI) | 2018-06-14 |
| Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients (NCT03618602) | Shanghai Theorion Pharmaceutical Co Ltd. | 2018-04-25 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (NCT06385483) | National Cancer Institute (NCI) | 2018-02-28 |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03266692) | Cogent Biosciences, Inc. | 2018-02-22 |
| Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma (NCT03201250) | University of Nebraska | 2018-02-21 |
| High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT03389347) | University of Washington | 2018-02-14 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) (NCT06390852) | National Cancer Institute (NCI) | 2017-08-21 |
| Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (NCT03158688) | Amgen | 2017-06-13 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) (NCT04439227) | National Cancer Institute (NCI) | 2017-03-24 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) (NCT06390865) | National Cancer Institute (NCI) | 2017-03-12 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) (NCT06385496) | National Cancer Institute (NCI) | 2017-03-12 |
| A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma (NCT02998047) | Actinium Pharmaceuticals | 2016-12-01 |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) (NCT06390826) | National Cancer Institute (NCI) | 2016-11-01 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (NCT06357975) | National Cancer Institute (NCI) | 2016-07-29 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (NCT06360575) | National Cancer Institute (NCI) | 2016-07-20 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) (NCT06357988) | National Cancer Institute (NCI) | 2016-06-20 |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) (NCT04439123) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (NCT04439344) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (NCT04439149) | National Cancer Institute (NCI) | 2016-05-05 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (NCT04439188) | National Cancer Institute (NCI) | 2016-03-21 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (NCT04439318) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) (NCT04439175) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167) | National Cancer Institute (NCI) | 2016-01-08 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (NCT04439292) | National Cancer Institute (NCI) | 2016-01-04 |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (NCT04439331) | National Cancer Institute (NCI) | 2015-11-19 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) (NCT04439136) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) (NCT04439279) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (NCT04439110) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) (NCT04439253) | National Cancer Institute (NCI) | 2015-08-12 |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02101944) | National Cancer Institute (NCI) | 2014-12-09 |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NCT02103335) | Celgene | 2014-06-05 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma (NCT01954784) | Case Comprehensive Cancer Center | 2013-10-07 |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib (NCT01775553) | Ajai Chari | 2013-09-01 |
| Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy (NCT02020941) | Attaya Suvannasankha | 2013-09-01 |
| Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (NCT01812720) | Mayo Clinic | 2013-08-01 |
| Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (NCT01676961) | NYU Langone Health | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (NCT01564537) | Takeda | 2012-08-01 |
| Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients (NCT01653106) | Ohio State University Comprehensive Cancer Center | 2012-04-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant (NCT01534143) | Barbara Ann Karmanos Cancer Institute | 2012-02-01 |
| Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma (NCT01447914) | National Cancer Institute (NCI) | 2011-11-01 |
| Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01212952) | Mayo Clinic | 2011-09-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide (NCT01301963) | Case Comprehensive Cancer Center | 2011-07-01 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma (NCT02037256) | Barbara Ann Karmanos Cancer Institute | 2011-07-01 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (NCT01658319) | Case Comprehensive Cancer Center | 2011-05-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia (NCT01118689) | Millennium Pharmaceuticals, Inc. | 2010-11-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (NCT01078441) | National Cancer Institute (NCI) | 2010-09-01 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (NCT01110135) | University of Washington | 2010-08-01 |
| Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (NCT01083602) | Novartis Pharmaceuticals | 2010-06-01 |
| Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma (NCT01155583) | Case Comprehensive Cancer Center | 2010-06-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (NCT01049945) | Mayo Clinic | 2010-02-01 |
| Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01034553) | Mayo Clinic | 2010-02-01 |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (NCT00998049) | Mayo Clinic | 2009-12-01 |